Therapeutic Apheresis in Metabolic Syndrome - Wikidata - awgldk - TriplyDB

Therapeutic Apheresis in Metabolic Syndrome

Therapeutic Apheresis in Metabolic Syndrome

http://www.wikidata.org/entity/Q58131385

about

Therapeutic Apheresis in Metabolic Syndrome

http://www.wikidata.org/entity/Q58131385

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2018

@uk

name

Therapeutic Apheresis in Metabolic Syndrome

@en

Therapeutic Apheresis in Metabolic Syndrome

@nl

type

label

Therapeutic Apheresis in Metabolic Syndrome

@en

Therapeutic Apheresis in Metabolic Syndrome

@nl

prefLabel

Therapeutic Apheresis in Metabolic Syndrome

@en

Therapeutic Apheresis in Metabolic Syndrome

@nl

P1433

Q58131385-A703B871-7F55-4554-B9EB-33B6CE8FBFC2

P1476

Q58131385-BB76F62A-0B63-4E90-82E5-CF9E90DA8F7D

P2093

Q58131385-94890EE4-FCB3-426C-B3D1-705FD044EEF1

P2860

Q58131385-04DA4205-AFBA-4271-BEE2-2C3E07A4EA78

Q58131385-08112839-69F4-4655-93DC-B118D86BE6AF

Q58131385-0B838DF9-019D-4653-A0FD-53FC8125334A

Q58131385-0D59EDC3-E099-4340-8186-9DED431974EF

Q58131385-116A4FBF-178C-4C03-A035-732D6295F351

Q58131385-11A334E5-112E-4174-B5D8-BC1EF9E5A5FD

Q58131385-12CC2AEB-7C62-4B51-9988-115FD990980B

Q58131385-1375E26F-1A66-438F-A0AF-1B4B07E289F5

Q58131385-13994C9E-B5B3-4843-9128-53505EAE061C

Q58131385-156C2CDF-13E5-4286-8DC5-3FF916AC7DA5

P304

Q58131385-A44FE3C6-44A1-4C61-B027-0DD1F0002E86

P31

Q58131385-1F192F72-86AF-4382-B308-10E580988B59

P356

Q58131385-761583D2-68FC-4A4E-AE99-AE229B0F0788

P407

Q58131385-D608B3F1-2C26-4825-9442-F3EFF726E4C9

P433

Q58131385-6545E309-F6B0-4849-BA72-42B93C72CA34

P478

Q58131385-5D5B002D-C838-41D6-B484-428B68178724

P577

Q58131385-899F14B8-D553-4AAB-BD6A-A15FB8C5C7F4

P698

Q58131385-5E1810E3-34D1-4285-A6C5-53A676D76FC2

P921

Q58131385-04BC0E43-D3A4-4310-8D3C-D43F52F5F1CD

Q58131385-CEC639FF-AD25-46C3-BD3A-829480A652AB

P932

Q58131385-CE0A5765-7399-44C8-A4D2-059FD91EF45B

P356

1871522218666180608114536

P1433

Immunology, endocrine & metabolic agents in medicinal chemistry

P1476

Therapeutic Apheresis in Metabolic Syndrome

@en

P2093

V A Voinov

http://www.w3.org/2001/XMLSchema#string

P2860

Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?

The role of metabolic syndrome in heart failure

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes

Glycated hemoglobin and its spinoffs: Cardiovascular disease markers or risk factors?

Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.

Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes.

Rheopheresis in patients with ischemic diabetic foot syndrome: results of an open label prospective pilot trial.

Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.

Diabetes, microalbuminuria and hypertension.

P304

38-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1871522218666180608114536

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30369968

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome

P932

6174637

http://www.w3.org/2001/XMLSchema#string